Stella Diagnostics

21/10/2021

StellaDX and Mayo Clinic are working to elucidate expression patterns crucial for GI's to optimize management strategies before neoplastic pathways predominate their patient's lower esophageal disease. For more info on our ongoing partnership, visit: https://bit.ly/2YiJovp

18/10/2021

Esophageal cancer is deadly with incidence rates increasing rapidly, especially in the U.S. A recent paper identifies the importance of early detection of Barrett's esophagus in patients to stop esophageal cancer before it starts:

15/10/2021

Stella Diagnostics is working to see beyond routine gross and microscopic screening of esophageal diseases to better inform gastroenterologists, oncologists and pathologists of the molecular expression trends indicative of disease stability or progression and carcinogenesis. Learn more:

Heartburn can occur in anyone, but chronic or severe heartburn can be a sign of gastroesophageal reflux disease (GERD) which can potentially lead to further ...

13/10/2021

Esophageal adenocarcinoma arises from dysplastic tissue of Barrett's esophagus, a complication of gastroesophageal reflux disease (GERD), and is the fastest increasing cancer in the United States with a 600% increase over the past 25 years. Learn more:

Current state of prognostication, therapy and prospective innovations for Barrett’s-related esophageal adenocarcinoma: a literature review

08/10/2021

Although men have a much higher risk of developing esophageal cancer, women should still undergo screening, especially if diagnosed with Barrett's esophagus. https://mayocl.in/39RGFvV

05/10/2021

To date, no randomized, controlled trials have shown endoscopic Barrett's esophagus screening to improve esophageal adenocarcinoma (EAC) patient survival rates. StellaDX's molecular diagnostics are being designed to more efficiently predict EAC progression and save patients' lives. Learn more:

Optimizing Patient Management Strategies for Esophageal Diseases

29/09/2021

Barrett's esophagus (BE) is a change in the tissue that lines the esophagus, and is one of the only known precursors to esophageal adenocarcinoma. Learn more about BE:

Barrett’s esophagus is a change in the cells lining your esophagus. Acid reflux (GERD) contributes to its development, but you can have the disorder without having GERD.

24/09/2021

Stella Diagnostics is a research-based organization offering clinically actionable diagnostic panels specific to the current disease state of a patient’s distal esophagus. Learn more about our work: https://bit.ly/3wO96EE

21/09/2021

Esophageal adenocarcinoma, which is linked to Barrett's esophagus, has one of the highest mortality rates in oncology, as more than half of patients diagnosed with EAC have already progressed to late-stage carcinogenesis at the time of diagnosis. More https://bit.ly/2YIaRXt

16/09/2021

Stella Diagnostics is working with industry-leading organizations like the Mayo Clinic, University of Kansas Medical Center, and mProbe to develop its first-line molecular diagnostic tools and improve the current standard screening protocols for esophageal diseases. For more details: https://bit.ly/3wO96EE

14/09/2021

Members of StellaDX's team review the current status of Barrett's esophagus monitoring and subsequent therapeutic strategies being used in patients who have progressed to cancer, while also discussing new diagnostic tools and therapeutic candidates for BE-related EAC:

Current state of prognostication, therapy and prospective innovations for Barrett’s-related esophageal adenocarcinoma: a literature review

13/09/2021

A recent report worked to determine the cell of origin of Barrett's esophagus and the mechanisms related to the malignant progression to esophageal adenocarcinoma. Learn more about the research:

Barrett’s esophagus appears to originate from the gastric cardia.